Separate and combined effects of DNMT and HDAC inhibitors in treating human multi-drug resistant osteosarcoma HosDXR150 cell line
about
Combination of azacitidine and trichostatin A decreased the tumorigenic potential of lung cancer cells.Histone Deacetylases in Bone Development and Skeletal Disorders.Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma.Identification of Synergistic, Clinically Achievable, Combination Therapies for OsteosarcomaChromatin modifiers and histone modifications in bone formation, regeneration, and therapeutic intervention for bone-related disease.Emerging approaches for histone deacetylase inhibitor drug discovery.A quinazoline-based HDAC inhibitor affects gene expression pathways involved in cholesterol biosynthesis and mevalonate in prostate cancer cells.Resveratrol-salicylate derivatives as selective DNMT3 inhibitors and anticancer agents.Immuno-regulated common markers but different network signatures in two associated cancers: evidences from epigenetic treatmentTherapeutic applications of histone deacetylase inhibitors in sarcoma.A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer.Histone deacetylation, as opposed to promoter methylation, results in epigenetic BIM silencing and resistance to EGFR TKI in NSCLC.Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma.
P2860
Q33813245-2966918F-544A-4C8B-8756-B829173CC5FFQ36146330-6B7236DC-C40F-4A03-9D4F-501F2A64A1BAQ36191943-B512DBA9-9740-4094-9A68-247DFFCE52B1Q36316518-FC2C9C6E-C128-4D4C-B503-118E880115EEQ38402465-A8819EB5-B47A-47F5-933E-6F3673C84708Q38431356-A12E2286-2D90-4991-88C9-6AA0E8946FADQ38804294-D666CAF9-F293-486E-AADB-C991B2484807Q38859365-43B4683F-5AFE-4A4C-AEF0-89116871BF25Q38993897-60A87C06-84D3-4F67-83B8-3DEFB56F6EA4Q39450827-3E16C08A-7555-4E82-AC8E-0EFDA351E617Q48199426-AC295EE8-3D57-47E4-BE21-A5786B50F595Q49335075-331E2F21-319A-40C3-9223-7DCF998102C0Q52689154-EDF3B53C-CB7E-4F40-9B58-1A37E197F31A
P2860
Separate and combined effects of DNMT and HDAC inhibitors in treating human multi-drug resistant osteosarcoma HosDXR150 cell line
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Separate and combined effects ...... teosarcoma HosDXR150 cell line
@ast
Separate and combined effects ...... teosarcoma HosDXR150 cell line
@en
Separate and combined effects ...... teosarcoma HosDXR150 cell line
@nl
type
label
Separate and combined effects ...... teosarcoma HosDXR150 cell line
@ast
Separate and combined effects ...... teosarcoma HosDXR150 cell line
@en
Separate and combined effects ...... teosarcoma HosDXR150 cell line
@nl
prefLabel
Separate and combined effects ...... teosarcoma HosDXR150 cell line
@ast
Separate and combined effects ...... teosarcoma HosDXR150 cell line
@en
Separate and combined effects ...... teosarcoma HosDXR150 cell line
@nl
P2093
P2860
P50
P3181
P1433
P1476
Separate and combined effects ...... teosarcoma HosDXR150 cell line
@en
P2093
Annalisa Roberti
Dario La Sala
Enrico Capobianco
Monia Taranta
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0095596
P407
P577
2014-04-22T00:00:00Z